Cassava Sciences, Inc. Made Headway

Cassava Sciences, Inc. (SAVA:NASDAQ) rocketted at $38.91, a gain of 28.4%. On Tue, Sep 20, 2022, SAVA:NASDAQ touched a New 2-Week High of $38.91. The stock appeared on our News Catalysts scanner on Thu, Sep 08, 2022 at 10:31 AM in the 'MISCELLANEOUS' category. From Tue, Sep 06, 2022, the stock recorded 60.00% Up Days and 63.64% Green Days

About Cassava Sciences, Inc. (SAVA:NASDAQ)

Pain Therapeutics Inc is a biopharmaceutical company. It develops proprietary drugs that offer improvements to patients and healthcare professionals. The company generally focuses on the drug development efforts on disorders of the nervous system, such as chronic pain. Pain Therapeutics operates in the single operating segment. Pain Therapeutics's drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The company's other product includes FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use.